|
Diabetes Prevention Program Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Diabetes Prevention Program conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Diabetes Prevention Program Clinical research trials and Diabetes Prevention Program medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Diabetes Prevention Program. Diabetes Prevention Program Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Diabetes Prevention Program clinical trial. Participants oftentimes recieve the finest healthcare available for their Diabetes Prevention Program condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "D" Clinical Trials Conditions > Diabetes Prevention Program  Diabetes Prevention Program
Diabetes Prevention Program
For Condition: Glucose Intolerance,Diabetes Mellitus, Non-Insulin-Dependent
Status: Completed
Sponsor(s): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) , National Institute on Aging (NIA),National Institute of Child Health and Human Development (NICHD),National Center on Minority Health and Health Disparities (NCMHD),Office of Research on Women's Health (ORWH)
Synopsis: The Diabetes Prevention Program is a nationwide clinical study to answer the question: Can Type 2 diabetes (also called noninsulin-dependent or adult-onset diabetes) be prevented or delayed? The study has recruited 3819 volunteers, who are at high risk of developing diabetes, at twenty-five medical centers in the United States. It is sponsored by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, and other Institute and corporate sponsors. Researchers will evaluate the efficacy of a lifestyle intervention and a pharmacological intervention in preventing or delaying Type 2 diabetes in persons with IGT, impaired glucose tolerance. Each person in the study will be followed for 3 to 6 years.
Details:
Eligibility:
Study Type: Interventional, Prevention, Randomized, Double-Blind, Placebo Control
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Impaired glucose tolerance (FPG 95-125 mg/dL and 2hr PG 140-199 mg/dL) - BMI >= 24 kg/m2 Exclusion Criteria: - Underlying disease likely to limit life span and/or increase risk of interventions - Conditions or behaviors likely to effect conduct of the DPP - Diabetes or disordered glucose metabolism - Suboptimally treated Thyroid disease - Fasting triglyceride level < 600 mg/dl - Exclusions related to medications
Total Enrollment: 3819
Location and Contact Information:
Overall Study Official:
SarahFowler, Principal Investigator,
George Washington University Biostatistics Center, Suite 750, 6110 Executive Blvd
Rockville, Maryland, 20852
United States
Additional Information:
Study ID Numbers: DPP; DK48489
Study Start Date: July 1996
Record last reviewed: July 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00004992
Other Diabetes Mellitus, Non-Insulin-Dependent Studies:
1. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
2. Evaluate the Role of Adding Amaryl to Non-Insulin Dependent Diabetes Mellitus Patients unresponsive to Maximum Dose Metformin & Thiazolidinedione
3. NNC 90-1170 Mechanism of Action: A double-blind, randomized, single-center, placebo-controlled, crossover study to examine beta-cell responsiveness to graded glucose infusion in subjects with type 2 diabetes
4. Disease Management and Educational Intervention Outcomes in High-Risk Diabetics
5. A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes
Related Studies:
Other Diabetes Mellitus, Non-Insulin-Dependent Clinical Trials
Other Maryland Clinical Trials
Other Rockville Clinical Trials
Diabetes Prevention Program
|
|
|
|
|
|
|
|
